Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 2:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 224 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Escitalopram Therapy Clear all
Completed Phase 1 Interventional

Multiple Ascending Dose Phase 1 Study of ALA-3000

NCT06965569
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
ALA-3000, Placebo, escitalopram, sertraline, duloxetine or venlafaxine XR
Drug
Lead sponsor
Alar Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
4
States / cities
Little Rock, Arkansas • St Louis, Missouri • Eatontown, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 4, 2026, 2:50 AM EDT
Completed No phase listed Observational Results available

STAR*D Alcohol: Treatment of Depression Concurrent With Alcohol Abuse

NCT00369746
View directory record Official record
Conditions
Major Depressive Disorder, Alcohol Use Disorder
Interventions
citalopram
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
674 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 4, 2026, 2:50 AM EDT
Recruiting Phase 1 Interventional

Pattern Separation in Major Depressive Disorder

NCT07139834
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
SSRI (escitalopram or sertraline), Extended-Release Memantine, Placebo
Drug
Lead sponsor
Jeffrey Miller
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 4, 2026, 2:50 AM EDT
Recruiting Phase 4 Interventional

Aβ Dynamics in LLMD

NCT05004987
View directory record Official record
Conditions
Alzheimer Disease, Major Depressive Disorder
Interventions
Escitalopram Oxalate, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
60 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
New York, New York • Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 4, 2026, 2:50 AM EDT
Completed No phase listed Observational

Escitalopram Neuroimaging Supplement

NCT01398865
View directory record Official record
Conditions
Body Dysmorphic Disorder
Interventions
PET scan and MRI scan
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 64 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 13, 2015 · Synced Oct 4, 2026, 2:50 AM EDT
Completed Phase 4 Interventional

Treatments for Anxiety: Meditation and Escitalopram

NCT03522844
View directory record Official record
Conditions
Anxiety Disorders, Generalized Anxiety Disorder, Panic Disorder, Social Anxiety Disorder, Agoraphobia
Interventions
Mindfulness-Based Stress Reduction, Escitalopram
Other · Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 75 Years
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 4, 2026, 2:50 AM EDT
Terminated Not applicable Interventional Results available

Combination Lexapro and Massage for Treatment of Depression in Older Adults

NCT00643162
View directory record Official record
Conditions
Depression
Interventions
Lexapro, Light touch, Massage
Drug · Behavioral
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
60 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Oct 4, 2026, 2:50 AM EDT
Completed Phase 4 Interventional Results available

Drug Therapy for Generalized Anxiety Disorder Among the Elderly

NCT00105586
View directory record Official record
Conditions
Anxiety Disorders, Generalized Anxiety Disorder
Interventions
Escitalopram
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
60 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Oct 4, 2026, 2:50 AM EDT
Completed Phase 4 Interventional

Safety and Efficacy of Eszopiclone in Patients With Generalized Anxiety Disorder

NCT00235508
View directory record Official record
Conditions
Insomnia, Generalized Anxiety Disorder
Interventions
Eszopiclone (Lunesta)
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
64
States / cities
Birmingham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 4, 2026, 2:50 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Stress and Inflammation in Late-Life Depression

NCT02389465
View directory record Official record
Conditions
Depression, Inflammation
Interventions
Escitalopram + Celecoxib, Escitalopram + Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
50 Years to 80 Years
Enrollment
119 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Oct 4, 2026, 2:50 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder

NCT01469377
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, Cariprazine
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
819 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
39
States / cities
Garden Grove, California • National City, California • Oceanside, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Oct 4, 2026, 2:50 AM EDT
Active, not recruiting Phase 4 Interventional

Sequential Multiple Assignment Randomized Trial for Bipolar Depression

NCT06433635
View directory record Official record
Conditions
Bipolar I Disorder, Depression
Interventions
Cariprazine, Aripiprazole/Escitalopram combination, Quetiapine, Lurasidone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
2,726 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
17
States / cities
Birmingham, Alabama • Bloomington, Indiana • Baltimore, Maryland + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 4, 2026, 2:50 AM EDT
Completed Phase 2 Interventional

Predicting Alcoholics' Treatment Responses to a Selective Serotonin Re-uptake Inhibitor (SSRI)

NCT00249405
View directory record Official record
Conditions
Alcoholism, Alcohol Abuse
Interventions
Citalopram + MI, Placebo + MI
Drug · Behavioral
Lead sponsor
University of Cincinnati
Other
Eligibility
21 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 3, 2010 · Synced Oct 4, 2026, 2:50 AM EDT
Completed Phase 3 Interventional Results available

Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction

NCT01364649
View directory record Official record
Conditions
Treatment Outcome
Interventions
Vortioxetine, Escitalopram, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
53
States / cities
Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 50 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2014 · Synced Oct 4, 2026, 2:50 AM EDT
Completed Not applicable Interventional

Lexapro in the Treatment of Patients With Postpartum Depression

NCT00277108
View directory record Official record
Conditions
Postpartum Depression
Interventions
Escitalopram (Lexapro)
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 6, 2008 · Synced Oct 4, 2026, 2:50 AM EDT
Completed Phase 4 Interventional Results available

Cognitive-Behavioral Therapy and Escitalopram for Generalized Anxiety Disorder(GAD)

NCT00219349
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Cognitive Behavioral Therapy, escitalopram
Behavioral · Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 19, 2017 · Synced Oct 4, 2026, 2:50 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Brain GABA Levels and Treatment Response in Major Depressive Disorder

NCT00464711
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 4, 2017 · Synced Oct 4, 2026, 2:50 AM EDT
Completed Phase 4 Interventional

VISN 20: Prophylactic Treatment of Interferon-Induced Depression in Hepatitis C Patients

NCT00108563
View directory record Official record
Conditions
Hepatitis C, Depression
Interventions
Citalopram or Placebo
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Oct 4, 2026, 2:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cellular Aging and Neurobiology of Depression Study

NCT00285935
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Standard Clinical Care with an SSRI
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years to 60 Years
Enrollment
228 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Oct 4, 2026, 2:50 AM EDT
Terminated Phase 4 Interventional

Galantamine Augmentation of Escitalopram for Treatment of Depression

NCT00423969
View directory record Official record
Conditions
Depression
Interventions
Galantamine, Escitalopram
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 18, 2007 · Synced Oct 4, 2026, 2:50 AM EDT
Terminated Phase 4 Interventional Results available

Escitalopram for Premenstrual Syndrome (PMS) in Teens: A Pilot Study

NCT00523705
View directory record Official record
Conditions
PMS
Interventions
escitalopram, placebo
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
15 Years to 19 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 6, 2014 · Synced Oct 4, 2026, 2:50 AM EDT
Completed Phase 2 Interventional Results available

Incorporating Patient Treatment Choice to Improve Treatment Retention in Depressed Hispanics

NCT00742573
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Antidepressants through Texas Medication Algorithm (TMA), Brief Interpersonal Psychotherapy (IPT-B)
Drug · Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 79 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Oct 4, 2026, 2:50 AM EDT
Completed Phase 4 Interventional Results available

Developing New Clinical Management Strategies

NCT02082392
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Oct 4, 2026, 2:50 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT02418585
View directory record Official record
Conditions
Treatment-resistant Depression
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
10
States / cities
Birmingham, Alabama • Orange, California • San Rafael, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 4, 2026, 2:50 AM EDT